Study Summary
This trial studies if a drug called dupilumab can help reduce symptoms of atopic dermatitis (eczema) in people aged 12 and older with moderate-to-severe symptoms.
- Atopic Dermatitis
- Eczema
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 27 Secondary · Reporting Duration: Baseline to Weeks 4, 12 and 24
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
1 Treatment Group
dupilumab
1 of 1
Experimental Treatment
120 Total Participants · 1 Treatment Group
Primary Treatment: dupilumab · No Placebo Group · Phase 4
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age Any Age · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How efficacious is dupilumab in promoting health and wellbeing?
"Thanks to it's Phase 4 status, dupilumab has earned a score of 3 indicating established safety." - Anonymous Online Contributor
Is there still enrollment capacity for this investigation?
"Affirmative. Clinicaltrials.gov states that the trial, initially published on November 1st 2023, is currently recruiting participants. A total of 120 patients are needed from 30 separate medical facilities." - Anonymous Online Contributor
How many different locations are hosting this research endeavor?
"Presently, 30 clinics are running this trial. Of these sites, Montgomery, Fremont and La Jolla have the most opportunities for participation. It is suggested that patients enroll in a clinic nearest to them so as to offset travel demands." - Anonymous Online Contributor
To what extent is participant enrollment in this investigation?
"This study necessitates the recruitment of 120 patients that match the trial's requirements. Sanofi, as the main sponsor, will be running this clinical test from multiple research centres including The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham in Montgomery, California and C2 Research Center, LLC in Fremont, Florida." - Anonymous Online Contributor